Clinical trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium SAN DIEGO and SUZHOU, China , Jan. 13, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. ... read more »

- Successful nomination of lead SAFEbody candidates triggers milestone payment - SAN DIEGO and SUZHOU, China , Dec. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based ... read more »

- Posters presented at the 63 rd American Society of Hematology Annual Meeting - SAN DIEGO and SUZHOU, China , Dec. 13, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based ... read more »

Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab SAN DIEGO and SUZHOU, China , Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage ... read more »

ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022 SAN DIEGO and SUZHOU, China , Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and ... read more »